Favourable clinical benefit of PD‐1/PD‐L1 inhibition has been observed in NSCLC patients with TP53 mutations or combinations of KRAS and TP53 mutations in the same tumour independent of TMB.34, 35, 36. Here, TP53 is linked to neoplasm.